- Home
- AMLX vs LEGN Comparison
AMLX vs LEGN Comparison
Compare AMLX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMLX | LEGN |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.7B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AMLX | LEGN |
|---|---|---|
| Price | $27.97 | $22.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 13 |
| Target Price | $43.00 | ★ $45.62 |
| AVG Volume (30 Days) | 1.3M | ★ 1.9M |
| Earning Date | 11-09-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $380,786,000.00 | N/A |
| Revenue This Year | N/A | $39.73 |
| Revenue Next Year | N/A | $23.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1612.94 | N/A |
| 52 Week Low | $10.83 | $16.24 |
| 52 Week High | $41.14 | $37.50 |
Technical Indicators
Market Signals| Indicator | AMLX | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 68.40 |
| Support Level | $26.12 | $17.08 |
| Resistance Level | $28.60 | $23.65 |
| Average True Range (ATR) | 1.31 | 1.09 |
| MACD | 0.17 | 0.42 |
| Stochastic Oscillator | 54.21 | 96.08 |
Price Performance
Historical ComparisonAbout AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.